首页> 美国卫生研究院文献>Gland Surgery >Management of anaplastic thyroid cancer
【2h】

Management of anaplastic thyroid cancer

机译:间变性甲状腺癌的治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Anaplastic thyroid cancer (ATC) is a deadly disease with a dismal prognosis. Molecular analyses of ATC tumors have yielded interesting results, which could help in understanding the underlying mechanisms of this aggressive disease process. Managing ATC can be challenging and includes rapid diagnosis, adequate staging, and interdisciplinary, multimodal treatments to optimize patient outcome. Treatments include surgical resection to gross negative margins when possible, as well as neo- or adjuvant treatment with chemotherapy or external beam radiation (XRT) for locoregional disease. New treatment strategies include evaluating the benefits of vascular disrupting agents and tyrosine kinase inhibitors for advanced ATC with driver mutations, which can be targeted. This review summarizes key concepts in managing ATC.
机译:间变性甲状腺癌(ATC)是一种致命的疾病,预后不良。 ATC肿瘤的分子分析已产生有趣的结果,这可能有助于了解这种侵袭性疾病过程的潜在机制。管理ATC可能具有挑战性,包括快速诊断,适当的分期和跨学科的多模式治疗以优化患者预后。治疗方法包括手术切除(可能时)至总切缘阴性,以及针对局部疾病的化学疗法或外照射(XRT)新辅助治疗。新的治疗策略包括评估血管破坏剂和酪氨酸激酶抑制剂对具有靶向作用的晚期ATC的益处。这篇综述总结了管理ATC的关键概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号